News
Fixed-Dose Combo Airsupra Approved as Rescue Therapy for Asthma
Airsupra is a first-in-class, pressurized metered dose inhaler, fixed-dose combination of albuterol and budesonide.
Your search for severe asthma returned 398 results
ACAAI 2022
Mepolizumab Shows Real-World Efficacy in Allergic and Non-Allergic Asthma
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
ACAAI 2022
Exacerbations Risk Exists for Patients With All Levels of Asthma Control/Severity
The researchers analyzed 351,870 US patients at least 12 years of age from the IBM MarketScan databases who received SABA for asthma from 2010 to 2017.
ACAAI 2022
Researchers Link Smell Loss, Disease Burden, and Dupilumab Efficacy in CRSwNP
Greater disease burden in chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with increased loss of smell severity. Outcomes of CRSwNP were significantly improved with dupilumab, regardless of loss of smell severity at baseline. These are among the post-hoc analysis findings presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific…
ACAAI 2022
Use of Biologics Reduces Exacerbations, Emergency Visits in Pediatric Asthma
Investigators assessed a real-world pediatric patients with asthma who used biologic therapy to identify their response to prescribed biologics and reasons for discontinuation of therapy as well as to characterize other attributes of this population.
ACAAI 2022
Allergen Exposure, Other Factors Predict Limited Airflow in Pediatric Asthma
“Children with AFL had significantly higher total blood and bronchoalveolar lavage (BAL) eosinophil count, total IgE, [immunoglobulin E] and greater number of positive allergen specific serum IgE,” the investigators noted.
ACAAI 2022
Uncontrolled Asthma in Hispanic/Latino Patients Improved With Tezepelumab
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
ACAAI 2022
Exhalation Delivery System With Fluticasone Improves Sinusitis Without Polyps
The study included 223 patients with moderate-severe disease based on baseline scores.
ACAAI 2022
Needle-Free Epinephrine Delivery Would Lead to Faster Allergy Response
"A needle-free option for administering epinephrine would be used more quickly after symptoms developed and would be easier to use versus an injectable device."
ACAAI 2022
Number of Patient-Reported Severe Asthma Triggers Predicts Morbidity
The observational study that enrolled 2847 adult patients with severe asthma receiving maintenance systemic corticosteroids, biologics, or uncontrolled on high-dosage inhaled corticosteroids and additional controllers.
